Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering.

26 Dec 2013

Madison Dearborn Partners signs definitive agreement to acquire Ikaria

Madison Dearborn Partners announced today that it has signed a definitive agreement under which it will acquire a majority ownership position in Ikaria, Inc., a leading provider of proprietary and innovative therapies for the critical care units in hospitals.

25 Dec 2013

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.

20 Dec 2013

Nature-engineered nanomotors could be used in targeted drug delivery

In the quest to shrink motors so they can maneuver in tiny spaces like inside and between human cells, scientists have taken inspiration from millions of years of plant evolution and incorporated, for the first time, corkscrew structures from plants into a new kind of helical "microswimmer."

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

The Ben & Catherine Ivy Foundation today announced a $3 million grant to the Translational Genomics Research Institute (TGen), Nemucore Medical Innovations Inc., and Barrow Neurological Institute at St. Joseph's Hospital and Medical Center to help fund significant brain tumor research in Arizona.

18 Dec 2013

Aerogen wins Medical Technology Company award for its innovative solutions to healthcare providers

Aerogen, a medical device and drug delivery company has been honoured as the Medical Technology Company of the Year Award 2013. Aerogen's patented vibrating mesh technology turns liquid medication into a fine particle mist, gently and effectively delivering drugs to the lungs of critically ill patients.

16 Dec 2013

Market research report on global and China insulin industry

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%.

12 Dec 2013

RBCC, Therakine reach major milestone in the development of new drug delivery technology

Rainbow Coral Corp. and its joint venture partner, Therakine, Ltd., are pleased to announce that they have reached a major new milestone in the development of a revolutionary new drug delivery technology.

12 Dec 2013

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

10 Dec 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

9 Dec 2013

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Adocia, a biotechnology company specializing in the development of ‘best-in-class’ medicines from already approved therapeutic proteins, announces today the signature of an exclusive license agreement with the CNRS, the University Bordeaux I, the Institut Polytechnique de Bordeaux and Aquitaine Science Transfert.

9 Dec 2013

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

For nearly half a century, contact lenses have been proposed as a means of ocular drug delivery that may someday replace eye drops, but achieving controlled drug release has been a significant challenge. Researchers at Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children's Hospital, and the Massachusetts Institute of Technology are one step closer to an eye drop-free reality with the development of a drug-eluting contact lens designed for prolonged delivery of latanoprost, a common drug used for the treatment of glaucoma, the leading cause of irreversible blindness worldwide.

9 Dec 2013

mHealth, Cloud in Healthcare and Regulatory Environments predicted to be the key subjects in 2014

Frost & Sullivan released today its three big predictions for the global healthcare market. Based on a '2013 Search for Growth' survey which involved 1835 executives in more than 40 countries worldwide, Frost & Sullivan's insight highlights new areas of growth. mHealth, Cloud in Healthcare and Regulatory Environments will be the key subjects in 2014 and beyond.

4 Dec 2013

USPTO awards patent to Sanovas' Abrading Balloon Catheter for Extravasated Drug Delivery

Sanovas, Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies announced today that the United States Patent and Trademark Office issued patent # 8,597,239 for the company's Abrading Balloon Catheter for Extravasated Drug Delivery.

4 Dec 2013

VISIUS iMRI and ClearPoint guidance platform make DBS surgery an option for children with dystonia

IMRIS Inc. and MRI Interventions, Inc. today announced that Cook Children's Medical Center in Fort Worth, Texas, is the first U.S. pediatric hospital to offer asleep deep brain stimulation surgery to children suffering from dystonia by utilizing the combination of MRI Interventions' ClearPoint Neuro Intervention System and an IMRIS VISIUS Surgical Theatre for real-time intraoperative image guidance and procedure visualization.

4 Dec 2013

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Nanosponges that soak up a dangerous pore-forming toxin produced by MRSA (methicillin-resistant Staphylococcus aureus) could serve as a safe and effective vaccine against this toxin. This "nanosponge vaccine" enabled the immune systems of mice to block the adverse effects of the alpha-haemolysin toxin from MRSA-both within the bloodstream and on the skin. Nanoengineers from the University of California, San Diego described the safety and efficacy of this nanosponge vaccine in the December 1 issue of Nature Nanotechnology.

2 Dec 2013

Drug Delivery News and Research

Further Reading

Oramed Pharmaceuticals to purchase $15,800,000 shares in registered direct offering

Madison Dearborn Partners signs definitive agreement to acquire Ikaria

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Nature-engineered nanomotors could be used in targeted drug delivery

New research assesses nanomedicine-based approaches for treating cancer

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Aerogen wins Medical Technology Company award for its innovative solutions to healthcare providers

Market research report on global and China insulin industry

RBCC, Therakine reach major milestone in the development of new drug delivery technology

GW Pharmaceuticals receives U.S. patent for treating glioma

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Researchers develop new drug-eluting contact lens for prolonged delivery of glaucoma medication

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

New drug delivery system successfully treats advanced-stage ovarian cancer in mice

Adocia gets development and commercialization rights in nanotechnology for drug delivery

Researchers one step closer to development of drug-eluting contact lens for glaucoma treatment

mHealth, Cloud in Healthcare and Regulatory Environments predicted to be the key subjects in 2014

USPTO awards patent to Sanovas' Abrading Balloon Catheter for Extravasated Drug Delivery

VISIUS iMRI and ClearPoint guidance platform make DBS surgery an option for children with dystonia

Nanosponge vaccine blocks adverse effects of alpha-haemolysin toxin from MRSA

Developing a best-in-class, end-to-end CMC platform eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo